Zacks Investment Research on MSN

Novavax grants license for use of Matrix-M adjuvant to Pfizer

Novavax NVAX announced a non-exclusive license agreement with Pfizer PFE, granting the latter access to its proprietary ...

Here's Why Pfizer Is Willing To Pay $500 Million For Novavax's Matrix-M

Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.

JPM26: Matrix-M Technology is central to Novavax’s strategy

Novavax’s CEO reviewed the company’s successes in 2025 and shared its growth strategy for 2026 and beyond at a recent ...
InvestorsHub on MSN

Novavax shares gain after Matrix-M adjuvant licensing deal with Pfizer

Novavax (NASDAQ:NVAX) shares climbed about 5% on Tuesday after the biotech group disclosed a non-exclusive licensing ...
Investing.com India

Novavax stock rises after licensing Matrix-M adjuvant to Pfizer

The agreement allows Pfizer to utilize Novavax’s Matrix-M adjuvant in up to two disease areas with its products. Under the ...
Business Wire

Imbed Biosciences Announces FDA IDE Approval for Silver-Gallium Synthetic Antimicrobial Matrix Clinical Study with Human Donor Site Wounds

MIDDLETON, Wis.--(BUSINESS WIRE)--Imbed Biosciences (“Imbed”), a pioneer in breakthrough wound care synthetic matrix technology, today announced the U.S. Food and Drug Administration (FDA) has ...